(+)- and (-)-N-allylnormetazocine binding sites in mouse brain: in vitro and in vivo characterization and regional distribution.
In vivo and in vitro binding studies, both in whole brain and in selected areas, indicate that non-identical (+)- and (-)-NANM sites exist in the mouse brain, and each exhibits a different regional distribution. The in vivo binding of (+)-3H-NANM was found to be saturable at pharmacologically relevant doses, and represents a relatively small (10-22%) portion of total brain (+)-3H-NANM concentrations. The in vivo binding of (+)-3H-NANM was selectively displaced by (+)-NANM and PCP, and more sensitive to haloperidol and (+)-ketocyclazocine than the (-)-3H-NANM site. The in vivo binding of (-)-3H-NANM was selectively displaced by (-)-NANM, and more sensitive to naloxone and (-) ketocyclazocine than the (+)-3H-NANM site, and insensitive to PCP. This study indicates that the investigation of NANM binding sites is possible using in vivo binding techniques, and that each isomer apparently binds, in the mouse brain, to a single class of distinct sites.
D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D003496:Cyclazocine / Q000031:analogs & derivatives; D016314:Ethylketocyclazocine / Q000031:analogs & derivatives*; D006220:Haloperidol; D066298:In Vitro Techniques; D051379:Mice; D009270:Naloxone; D010620:Phenazocine / Q000031:analogs & derivatives* / Q000378:metabolism; D010622:Phencyclidine; D011957:Receptors, Opioid / Q000378:metabolism*; D017480:Receptors, sigma; D013237:Stereoisomerism
D011957:Receptors, Opioid; D017480:Receptors, sigma; D009270:Naloxone; D016314:Ethylketocyclazocine; C012395:ketazocine; C012134:SK&F 10047; D010620:Phenazocine; D010622:Phencyclidine; D003496:Cyclazocine; D006220:Haloperidol